Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Corning Incorporated (GLW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Corning Incorporated — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $299.01 (market cap $39.89B), while Corning Incorporated trades at $184.25 (market cap $164.29B). The key difference: Corning Incorporated is far larger — about 4.1× Alnylam Pharmaceuticals, Inc.'s market cap, and Corning Incorporated pays a 0.59% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | GLW | |
|---|---|---|
Market Cap | $39.89B | $164.29B |
Sector | Health | Technology |
52-Week High | $491.22 | $255.79 |
52-Week Low | $278.09 | $51.60 |
Enterprise Value | $38.15B | $172.46B |
Dividend Yield | — | 0.59% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
GLW trades at $190.85, down 0.87% on the day, with a bullish technical signal supported by moving averages and oversold RSI-6 at 12.45. Recent earnings beats in Q3 2025-Q1 2026 and strong 2025 revenue growth to $15.63B highlight fundamental strength. Analyst consensus is bullish with a $208.60 price target, though high P/E of 91.77 raises valuation concerns. News outlets like Barron's (July 10, 2026) note AI-driven partnerships as a key catalyst amid recent volatility.
Outlook remains positive with AI infrastructure demand fueling growth, but risks include elevated debt levels and competitive pressures. The stock offers a dividend yield of approximately 0.29% with consistent payouts. Investors should weigh robust earnings momentum against rich valuations and macroeconomic headwinds for balanced exposure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Corning Incorporated
Corning Inc is a leader in materials science, specializing in the production of glass, ceramics and optical fiber. The firm supplies its products for a wide range of applications, from flat-panel displays in televisions to gasoline particulate filters in automobiles to optical fiber for broadband access, with a leading share in many of its end markets.
Read more on GLW →
